How Long Can You Stay on Weight Loss Injections?

How long can you stay on weight loss injections is one of the most common questions asked by people considering or already using medicines such as semaglutide (Wegovy) or tirzepatide (Mounjaro). Unlike short-term dieting aids, these medicines are licensed by the MHRA for chronic weight management, meaning treatment may continue indefinitely for suitable patients. Duration depends on individual clinical response, tolerability, and whether you are accessing treatment privately or through the NHS, where NICE appraisals and local commissioning criteria apply. This article explains what current UK guidance says and what to expect over the longer term.

How long can you stay on weight loss injections in the UK?

There is no fixed upper time limit for private prescribing; both Wegovy and Mounjaro are MHRA-licensed for chronic weight management, with duration determined by ongoing clinical review. NHS treatment is subject to NICE appraisal criteria and local ICB commissioning decisions.

There is no fixed upper time limit on how long you can stay on weight loss injections in the UK for private prescribing, and current clinical guidance treats obesity as a long-term, often lifelong, condition requiring sustained management. Medicines such as semaglutide (Wegovy) and tirzepatide (Mounjaro) are both authorised by the MHRA for chronic weight management in adults, and the word "chronic" in their licences reflects the expectation that treatment may continue indefinitely for suitable patients.^[2][16] Neither the Wegovy nor the Mounjaro UK Summary of Product Characteristics (SmPC) specifies a maximum treatment duration.^[15][16]

On the NHS, the position is different. Treatment is subject to local Integrated Care Board (ICB) commissioning decisions and to the continuation criteria set out in the relevant NICE technology appraisals (TA875 for semaglutide and TA1026 for tirzepatide). These appraisals include review points and response thresholds that must be met for NHS-funded treatment to continue, and local ICBs may apply additional criteria. Duration on the NHS is therefore not open-ended in the same way as private prescribing, and patients should discuss their specific pathway with their prescriber or ICB.

In all settings, duration is determined by individual clinical review rather than a blanket rule. A prescriber will assess whether you are still benefiting from treatment, whether side effects remain manageable, and whether your weight and health markers are stable.

Through a regulated private provider, continuation is governed by ongoing clinical assessment. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where medicines such as Mounjaro or Wegovy may be considered if clinically appropriate.

These medicines work best alongside sustained lifestyle changes. Prescribers will typically want to see that dietary and physical activity goals are being maintained alongside the medication, as this combination supports the best long-term outcomes.

What do NICE guidelines say about long-term use?

NICE appraisals TA875 and TA1026 require treatment to be reviewed at defined intervals, with continuation dependent on achieving a clinically meaningful weight loss response. Neither appraisal sets a universal maximum treatment duration.

NICE recommends semaglutide (Wegovy) under technology appraisal TA875 and tirzepatide (Mounjaro) under TA1026 for use within specialist weight management services.^[5][6] Both appraisals include provisions for ongoing treatment review rather than a fixed stop date, but they do specify that treatment should be reviewed at defined intervals to confirm that a clinically meaningful weight loss response has been achieved before continuation is supported.

For semaglutide (TA875), NICE specifies that treatment should be stopped if a patient has not lost at least 5% of their initial body weight by a defined review point.^[3][4] The precise review timepoints and response thresholds for tirzepatide are set out in TA1026. Readers should consult the published appraisals directly for the exact figures, as these criteria are subject to update. These review criteria are designed to ensure that NHS resources are directed to those who are responding to treatment, not to impose an arbitrary time cap.

Beyond the initial response check, neither TA875 nor TA1026 sets a universal maximum duration for NHS-funded treatment, though local ICB commissioning decisions may introduce additional criteria or review points. The underlying principle is that obesity is a chronic relapsing condition, and that effective treatment should be maintained for as long as it continues to provide clinical benefit and remains safe and tolerable for the individual.

It is also important to understand that NICE recommends these medicines but does not approve them. The MHRA grants marketing authorisation, and NHS availability depends on both NICE guidance and local ICB commissioning, which are separate processes.

What happens to your weight if you stop the injections?

Weight regain is common after stopping, with clinical trial data showing substantial regain within one to two years of discontinuation. This reflects the biology of obesity rather than a failure of willpower.

Weight regain is common after stopping weight loss injections. Clinical trial data, including the STEP 1 extension study for semaglutide, show that a substantial proportion of lost weight can return within one to two years of discontinuation.^[7][8] Evidence for tirzepatide cessation is more limited at present, but the underlying mechanism is similar. This is not a failure of willpower but a reflection of the underlying biology of obesity: the hormonal and metabolic signals that drive appetite and fat storage reassert themselves once the medication is withdrawn.

Semaglutide and tirzepatide work by mimicking gut hormones (GLP-1 and, in the case of tirzepatide, GIP) that regulate appetite, gastric emptying and insulin secretion.^[14][16] When these medicines are stopped, appetite signals return towards their pre-treatment levels, and energy intake tends to increase. Without the pharmacological support, maintaining the same calorie deficit becomes significantly harder for most people.

This does not mean that stopping is always the wrong decision, but it does mean that any plan to discontinue should be made carefully and with clinical support. Strategies that may help preserve weight loss after stopping include:

• Continuing structured dietary and physical activity programmes

• Regular follow-up with a healthcare professional or dietitian

• Monitoring weight at home and seeking early review if significant regain begins

• Discussing with your prescriber whether a planned pause or a change in approach is more appropriate than stopping abruptly (note that current evidence on tapering to prevent regain is limited, so this is a discussion point rather than an established recommendation)

For some people, the goal may be to use injections as a bridge to establishing sustainable habits, after which they can maintain their weight without medication. For others, long-term or indefinite treatment may be the most clinically appropriate path. This decision should always be made in partnership with a prescriber.

Are there any risks to staying on them for years?

Long-term risks include gastrointestinal side effects, gallbladder events, and acute pancreatitis, which requires urgent medical review if severe abdominal pain develops. Regular clinical monitoring is essential for safe long-term use.

Staying on weight loss injections for several years carries a manageable but real set of risks that should be monitored through regular clinical review. The long-term safety profiles of semaglutide and tirzepatide are still being characterised, as these medicines have only been in widespread use for weight management since the early 2020s, and post-marketing surveillance continues to add to the evidence base.

The most commonly reported side effects with both medicines are gastrointestinal, including nausea, vomiting, diarrhoea and constipation. These tend to be most pronounced during dose escalation and often improve over time, but some people experience persistent symptoms. Gallbladder-related events, including gallstones and cholecystitis, have been reported with GLP-1 receptor agonists, and this risk may be relevant over longer treatment periods, particularly with rapid weight loss.^[9][10]

Acute pancreatitis has been reported with both medicines, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.^[11] The UK SmPCs do not quantify the magnitude of this risk. If you develop persistent severe abdominal pain, particularly pain that radiates to the back, you should stop the medicine and seek urgent medical review promptly, as these can be symptoms of pancreatitis.

For people with pre-existing pre-proliferative or proliferative diabetic eye disease, rapid improvement in blood glucose control has been associated with transient worsening of diabetic retinopathy, and this should be discussed with a prescriber before starting treatment.

If you are due to have surgery or a procedure requiring anaesthesia, inform your surgical and anaesthetic team that you are taking a GLP-1 receptor agonist and follow their local guidance on whether to hold doses before the procedure.

Regular clinical review, including blood pressure, heart rate and any new symptoms, remains the cornerstone of safe long-term use. Healthcare professionals and patients can report suspected side effects to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Who decides when it is time to come off weight loss injections?

The decision to stop should always be made jointly with a qualified prescriber, who will assess weight trajectory, side effects, and health markers. Both medicines must be stopped if pregnancy occurs.

The decision to stop weight loss injections should always be made jointly between you and a qualified prescriber, and should never be taken unilaterally or based on cost alone. A prescriber will weigh up several factors before recommending discontinuation, including your current weight and trajectory, any side effects you are experiencing, your cardiovascular and metabolic health, and your personal goals and preferences.

There are specific clinical circumstances in which stopping is strongly advised. Both the Wegovy and Mounjaro SmPCs advise that these medicines should not be used during pregnancy or breastfeeding.^[14] Women of childbearing potential should use effective contraception during treatment. The UK SmPC for tirzepatide (Mounjaro) advises that women using oral contraceptives should add a non-oral contraceptive method for four weeks after starting treatment and for four weeks after each dose increase, because gastric slowing during this period may reduce oral contraceptive absorption.^[15][13] If you become pregnant while taking either medicine, you should stop it and contact your GP.

Other reasons a prescriber might recommend stopping include:

• Lack of ongoing clinical response after an adequate trial period

• Development of a contraindication or serious adverse effect

• A planned surgical procedure: inform your surgical and anaesthetic team in advance and follow their local guidance on holding doses before the procedure

• Patient choice, after a full discussion of the likely consequences

If you are considering stopping, speak to your GP or prescribing clinician before doing so. Do not contact 999 or A&E unless you are experiencing a life-threatening emergency. For urgent advice outside GP hours, NHS 111 is the appropriate first point of contact. Planned decisions about stopping or pausing treatment should always go through your regular prescriber.

Scientific References

1. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
2. First GLP-1 tablet for weight loss approved in the UK.
3. Semaglutide for managing overweight and obesity (TA875) – Recommendations.
4. Overview: Semaglutide for managing overweight and obesity (TA875).
5. Tirzepatide for managing overweight and obesity (TA1026) – Recommendations.
6. Overview: Tirzepatide for managing overweight and obesity (TA1026).
7. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension study).
8. Trajectory of weight regain after cessation of GLP-1 receptor agonists.
9. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases.
10. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
11. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
12. NG242 Diabetic retinopathy: management and monitoring – evidence review C (effectiveness of intensive treatments to lower blood glucose levels).
13. The impact of tirzepatide and glucagon-like peptide-1 receptor agonists on oral hormonal contraceptive absorption.
14. GLP-1 medicines for weight loss and diabetes: what you need to know.
15. Mounjaro KwikPen – Patient Information Leaflet.
16. Wegovy – European Public Assessment Report.

Frequently Asked Questions